Article: Too much of a good thing in Nature Reviews Cancer
April 30, 2024
Article: The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy in Cancer Cell
June 10, 2024
Lixte’s CEO Bas van der Baan presented at MedInvest Biotech and Pharma Conference, April 3-4, 2024. The MedInvest Conference is a leading conference series in Biotech and MedTech. Each conference is focused on a specific indication (e.g., oncology, neurology, etc.) or area of healthcare (drug development, MedTech). Watch the investor presentation to learn more about the Lixte as a biotech company, its impact in the field of oncology and how LB-100 strongly enhances the efficacy of both chemotherapies and immunotherapies.
